New Alberta ClarityDX prostate cancer blood test ‘groundbreaking’: developers
Global News
The ClarityDX test is touted as three times more accurate at discovering clinically significant prostate cancer than current screening methods.
The developers of a new prostate cancer test say it’s a groundbreaking advancement.
The ClarityDX prostate test has been developed by Edmonton-based company Nanostics, with support from the Alberta Cancer Foundation, and it’s now available in the province.
“It’s a non-invasive, easy to perform blood test that increases that accuracy to the point where we can be really much more confident about whether we can recommend a man for a biopsy or not,” Dr. John Lewis, University of Alberta oncology professor and CEO of Nanostics, said.
Men aged 40 to 75 who have gone through screening and have an elevated prostate-specific antigen (PSA) result can now get in the test in the province.
“That will really change the way men both figure out if they have prostate cancer and make critical decisions about whether to treat it or not,” Lewis said.
Most men are encouraged to begin getting PSA tests at the age of 50.
Lewis said the ClarityDX test is three times more accurate at discovering clinically significant prostate cancer than current screening.
The company said clinical data show ClarityDX could reduce unnecessary prostate biopsies by up to 35 per cent.